Related Experiment Video
Updated: Feb 3, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma
David B Zhen1, Andrew Coveler1, Silvia Zanon2
1Division of Medical Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has significantly grown and helped identify new therapeutic targets. The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies. We review the major biological mechanisms in PDAC and discuss current and future directions for molecularly targeted therapies in this disease.
Insights
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer. Advances in understanding molecular changes offer new biomarker-driven therapies, including immune checkpoint inhibitors and PARP inhibitors, improving treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents a significant challenge due to limited effective treatments.
- Recent advancements have elucidated key molecular alterations driving PDAC.
- Identifying these alterations is crucial for developing targeted therapies.
Purpose of the Study:
- To review the major biological mechanisms underlying PDAC.
- To discuss current and future directions for molecularly targeted therapies in PDAC.
- To highlight the impact of biomarker-driven therapeutic strategies.
Main Methods:
- Literature review of molecular mechanisms in PDAC.
- Analysis of current and emerging targeted therapies.
- Evaluation of biomarker-driven treatment successes.
Main Results:
- Significant progress has been made in understanding PDAC molecular landscape.
- Biomarker-driven therapies, such as immune checkpoint inhibitors and PARP inhibitors, show promise.
- Targeting hyaluronan with PEGPH20 is effective in specific patient populations.
Conclusions:
- Molecular insights are paving the way for more effective PDAC treatments.
- Biomarker-guided therapies represent a critical advancement in managing PDAC.
- Future research should focus on further refining molecularly targeted approaches for PDAC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Gene Therapy
Molecular Models
Molecular Orbital Theory II
Molecular Orbital Theory I
Predicting Molecular Geometry

